SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Human Genome Sciences, Inc. (HGSI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Bogdanoff who wrote (234)10/12/1998 11:21:00 PM
From: Steven Rachbach  Read Replies (1) of 1127
 
Thanks for your response and I agree entirely with you. One never knows what's going to happen: perhaps a drug will be found to cure all cancers which would obviate the need for MPIF entirely. On the other hand, MPIF might work so well that higher and more frequent cycles of chemotherapy could be the norm. Also, if intravenous KGF-2 works well for mucositis (another side effect of chemotherapy), then perhaps patients getting intense chemotherapy might get an HGSI cocktail of MPIF and KGF-2. More importantly, unlike most other drug companies, HGSI has over 2000 gene patents and who knows how many of those will turn out to have therapeutic value.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News